. 2021 Jun 29;13(6):e16046. doi: 10.7759/cureus.16046

Table 2. GRADEpro summary of findings.

^aheterogeneity; ^blimited studies; ^cwide confidence interval; *significant effect; ⨁◯ symbols indicating certainty of evidence

CI: confidence interval; MD: mean difference; HbA1C: glycosylated hemoglobin; RR: risk ratio

Patient or population: Type 2 diabetic patients
Setting: Asian population
Intervention: Insulin degludec
Comparison: insulin glargine
Outcomes	Anticipated absolute effects^* (95% CI)		Relative effect (95% CI)	№ of participants (studies)	The certainty of the evidence (GRADE)
Outcomes	The risk with insulin glargine	The risk with Insulin degludec	Relative effect (95% CI)	№ of participants (studies)	The certainty of the evidence (GRADE)
Fasting blood sugar	The mean fasting blood sugar was 0	MD 4.45 lower (13.32 lower to 4.43 higher)	-	508 (3 studies)	⨁⨁⨁◯ MODERATE ^{a, b}
Decrease in HbA1c	The mean decrease in HbA1c was 0	MD 0.12 higher (0.12 lower to 0.35 higher)	-	480 (2 studies	⨁⨁⨁◯ MODERATE ^b
Risk of hypoglycemia	506 per 1,000	491 per 1,000 (405 to 592)	RR 0.97 (0.80 to 1.17)	473 (2 studies)	⨁⨁◯◯ LOW ^{a, b, c}